The LARP4B Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the LARP4B gene in the Raji B lymphoblast cell line. This product provides a loss-of-function model for investigating the roles of the La-related protein 4B (LARP4B) in mRNA metabolism and translation regulation. The polyclonal knockout format ensures a heterogeneous population of edited cells, suitable for functional studies without clonal selection biases.
Raji cells are a well-characterized human cell line derived from a Burkitt lymphoma patient. As B lymphocytes with lymphoblastoid morphology, they retain key features of B-cell biology, including antigen presentation capacity and the potential for antibody production. These cells are widely employed as a model system for B-cell malignancies, particularly Burkitt lymphoma, due to their transformed phenotype and well-defined genetic background, including MYC deregulation.
LARP4B is an RNA-binding protein that specifically interacts with polyadenylated mRNAs via its La module and PABPC1, stabilizing target transcripts and promoting their translation. It functions within a network involving translation initiation factors such as eIF4E and ribosomal components, thereby enhancing the expression of proliferation-associated and cell cycle-regulatory mRNAs. LARP4B activity is influenced by upstream regulators including MYC, mTOR signaling, and growth factor pathways. Its interaction with PABPC1 and the translation machinery underscores its role as a post-transcriptional regulator connecting mRNA stability to protein synthesis and cell growth.
In the context of Raji Burkitt lymphoma cells, disruption of LARP4B is expected to compromise the stabilization and efficient translation of mRNAs driving oncogenic proliferation. Loss of LARP4B function may reduce the expression of key cell cycle regulators and proliferation-associated factors, impairing cellular growth and potentially attenuating tumorigenic properties. This knockout model therefore provides a relevant tool to dissect post-transcriptional mechanisms that sustain B-cell lymphoma, and to evaluate LARP4B as a vulnerability in MYC-driven malignancies.
Researchers can utilize this polyclonal knockout cell population to examine mRNA stability through actinomycin D chase experiments, translation efficiency by polysome profiling, and target gene expression via RT-qPCR and Western blotting. Proliferation assays (MTS/XTT) and flow cytometry for cell cycle progression and apoptosis permit assessment of functional consequences upon LARP4B loss. These applications support drug target validation studies and functional genomics screening in the RNA-binding protein network. For additional information or custom requests, please contact Ascent Research.
